Amniotics AB 

Amniotics AB (publ) develops stem cell-based therapeutics to treat severe life-threatening diseases. The company's lead drug candidate is PulmoStem for the treatment of lung disease. It also develops CogniStem for the treatment of CNS indications; NephroStem for the treatment of kidney-specific indications; CutiStem for the treatment of dermatological indications; and AMNI-NK003. The company offers contract development and contract manufacturing services for advanced therapy medicinal products to the pharmaceutical industries, universities, and hospitals. Amniotics AB (publ) was incorporated in 2015 and is based in Lund, Sweden.